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Abstract Background: Prompt surgical intervention supplemented by appropriate
antimicrobial therapy is usually required for successful treatment of complicated
intra-abdominal infections. The objective of this study was to further evaluate the
efficacy and safety of ertapenem relative to ceftriaxone/metronidazole as
treatment for complicated intra-abdominal infections.
Methods: Adult patients with intra-abdominal infections requiring surgery were
eligible for this open-label randomized trial comparing ertapenem 1 g daily with
ceftriaxone 2 g daily plus metronidazole 30 mg/kg/day. The primary efficacy
outcome was the clinical response rate in clinically and microbiologically evaluable
participants at the test-of-cure (TOC) visit 2 weeks after discontinuation of
therapy. All treated patients were included in the safety analysis.
Results: Participant demographics, disease characteristics, and duration of therapy
in both treatment groups were generally similar. Escherichia coli was the most
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26 N.S. Navarro et al.commonly isolated baseline pathogen, recovered in 52% of cases in each treatment
group. Favorable clinical responses were achieved at TOC in 143 (96.6%) of 148
ertapenem recipients and in 146 (96.7%) of 151 ceftriaxone/metronidazole
recipients. The frequencies of drug-related adverse events, most commonly
nausea, diarrhea, vomiting, and elevated platelet count, were generally compa-
rable in both treatment arms. Four ertapenem recipients (1.8%) and one
ceftriaxone/metronidazole recipient (0.4%) experienced serious drug-related
adverse events.
Conclusions: In this study, ertapenem and ceftriaxone/metronidazole were
comparably effective treatments for adult patients with complicated intra-
abdominal infections.
ª 2005 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.Introduction
Complicated intra-abdominal infections require
appropriate operative intervention as well as anti-
microbial therapy covering the most likely aerobic
and anaerobic pathogens.1e7 Antimicrobial regi-
mens used to treat intra-abdominal infections
should be broadly active against most Enterobac-
teriaceae and members of the Bacteroides fragilis
group.3,5 Ertapenem is a long-acting parenteral
Group I carbapenem with in vitro activity against
most bacterial pathogens causing routine commu-
nity-acquired infections.7e15 Ertapenem does not
have reliable activity against Pseudomonas aerugi-
nosa or enterococcal species, but coverage of these
organisms may not be necessary for successful
treatment of most community-acquired intra-
abdominal infections.3,5,16,17 In an earlier randomized
Phase II clinical trial, the efficacy of ertapenemwas
comparable to the combination of ceftriaxone and
metronidazole18 in the treatment of complicated
intra-abdominal infections. The present study com-
pared ertapenem as once daily monotherapy to
a standard regimen of ceftriaxone/metronidazole
for complicated intra-abdominal infections.
Methods
Study design
This international, Phase IV, randomized, open-
label study was conducted at 53 centers in Latin
America, Europe, Asia, Australia and South Africa
from January 2002 to February 2003. Institutional
review boards at each site approved the protocol,
and informed consent was obtained from all
participants. Hospitalized patientsR 18 years of
age with clinical evidence of an intra-abdominal
infection requiring open or laparoscopic surgical
intervention were eligible for the study if theinfection extended beyond the wall of a hollow
organ. For patients enrolled preoperatively, clini-
cal evidence of an intra-abdominal infection had
to include fever, leukocytosis, hypotension, tachy-
cardia and tachypnea, or altered mental status.
Exclusion criteria included pregnancy or lactation,
history of serious allergy or intolerance to either
study drug, rapidly progressive or terminal illness,
chronic immunosuppressive therapy, known infec-
tion with human immunodeficiency virus, APACHE
II scoreO 30, concurrent infection that could
interfere with evaluation of response to study
therapy, ischemic bowel disease, uncomplicated
cholecystitis, acute necrotizing pancreatitis, trau-
matic bowel perforation if surgery was performed
within 12 h of perforation, perforated gastroduo-
denal ulcer if surgery was performed within 24 h
of perforation, any primarily noninfectious intra-
abdominal process, need for peritoneal or hemodial-
ysis, acute hepatic failure, serum alanine or
aspartate aminotransferase levelsO 6 times the
upper limit of normal, bilirubin or alkaline phos-
phatase levelsO 3 times the upper limit of normal,
and systemic antimicrobial therapy for O24 h in
the 72-h period immediately prior to study entry
unless the patient had failed that therapy. Patients
were withdrawn from the study when surgical
intervention did not occur within 24 h after di-
agnosis or if all pathogens were resistant to either
study drug. In the case of polymicrobial infection,
the patient could remain in the study if at least
one isolate was susceptible to both study drugs.
Participants were randomized 1:1 to receive
ceftriaxone 2 g/day in 1 or 2 daily doses plus
metronidazole 30 mg/kg/day in 2e4 daily doses or
ertapenem 1 g once a day via an Interactive Voice
Recognition System based on a randomization
schedule that was generated by a computer pro-
gram. A block size of 8 was used. The Interactive
Voice Recognition System allowed the randomiza-
tion to be blinded. No stratification factors were
used for generating the randomization list. All
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order. Patients did not receive an allocation number
until they hadmet all inclusion criteria for the study
and were ready to enter the treatment phase of the
study. Ceftriaxone and ertapenem could be admin-
istered intravenously or intramuscularly; metroni-
dazole could be given intravenously or orally. Other
than the addition of vancomycin or teicoplanin for
infections caused by resistant gram-positive patho-
gens, concomitant antibacterial agents were not
permitted by protocol. Suggested treatment length
was 4e14 days, but the actual duration was left to
the discretion of the investigators.
Aerobic and anaerobic cultures of blood and
intraoperative specimens were collected at base-
line and processed in the clinical microbiology
laboratory of the participating hospitals. Aerobic
and facultatively anaerobic isolates were tested
for susceptibility to ertapenem and ceftriaxone
by disk diffusion or microtiter dilution methodo-
logy according to the guidelines of the National
Committee for Clinical Laboratory Standards
(NCCLS).19,20 Routine susceptibility testing of strict
anaerobes was not required per protocol.
Assessments of efficacy and safety
Participants were evaluated daily during study
therapy, at the discontinuation of study therapy,
and 2 and 4 weeks post-therapy. The primary
efficacy endpoint was designated a priori as the
proportion of clinically andmicrobiologically evalu-
able patients with a favorable clinical assessment
at the ‘‘test-of-cure’’ (TOC) visit 2 weeks after
completion of study therapy. Clinical responses
were classified as cure (complete or significant
resolution of all signs and symptoms related to
the index infection such that no further antimicro-
bial therapy or surgical intervention for infection
was necessary), failure (persistence or recurrence
of the index infection; death attributable to intra-
abdominal infection; a second surgical procedure;
or a post-operative wound infection), or indeter-
minate (data inadequate for assessment of efficacy
or cause of death). Patients with indeterminate
clinical responses were excluded from the primary
analysis. Microbiological responses were recorded
for each baseline pathogen. Favorable microbio-
logical responses included eradication of the
pathogen(s) that was documented or presumptive
(no material available for culture in clinically cured
patients); unfavorable microbiologic responses in-
cluded persistence of the pathogen(s) whether
documented or presumed (no material available
for culture in patients who had clinical failure).Microbiological responses for enterococci and
methicillin-resistant Staphylococcus aureus in pa-
tients treated with vancomycin or teicoplanin were
considered to be indeterminate; however, these
patients remained clinically evaluable and were
also evaluable for the overall microbiological out-
come provided that other pathogens susceptible to
both study drugs were isolated at baseline. Patients
with indeterminate microbiological responses for
all their baseline isolates were considered to be
microbiologically nonevaluable. Clinical responses
were assessed by the site investigator who was not
blinded to the treatment assignment, whereas the
microbiological response was determined by the
clinical monitor while still blinded to the treatment
assignment.
Patients were monitored for clinical adverse
experiences throughout the study. The investiga-
tor rated the intensity of any clinical adverse
event and judged the likelihood of its relation to
the study drug. Adverse events determined by the
investigator to be possibly, probably, or definitely
related to study therapy were categorized as drug-
related for the purposes of the safety analysis.
Study populations
The different populations were defined by the
clinical monitor in a blinded fashion. The treated
population included all randomized patients who
received at least 1 dose of study therapy. The
modified intent-to-treat (MITT) population included
all treated patients who met the disease defini-
tion. The clinically evaluable population was com-
posed of MITT patients with sufficient information
to determine outcome, no extraneous issues that
confounded outcome assessment, and if baseline
pathogens were recovered, at least one isolate
susceptible to both study drugs (anaerobes were
presumed susceptible). Clinically and microbiolog-
ically evaluable patients encompassed a subset of
the clinically evaluable population in whom a base-
line pathogen was identified and a microbiological
response assessed.
Statistical analysis
The primary hypothesis of the study was that
ertapenem would be at least as effective as
ceftriaxone/metronidazole measured by the pro-
portion of patients in the clinically and microbio-
logically evaluable population with a favorable
clinical response at the TOC visit after excluding
patients with indeterminate clinical responses.
The primary efficacy endpoint was the proportion
of clinically and microbiologically evaluable
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the TOC visit. For the primary endpoint, the
difference between response rates in the 2 treat-
ment groups along with the asymptotic 95% confi-
dence interval (CI) was calculated. Ertapenem was
to be considered noninferior to ceftriaxone/met-
ronidazole if the 95% CI for the difference in
response rates (ertapenem minus ceftriaxone/
metronidazole) contained 0 and its lower bound
was not below 15%.
Assuming an 80% response rate for both groups
and one-sided significance level of 0.025, 150
evaluable patients per group would be needed in
order to have 90% power to demonstrate that the
lower limit of the two-sided 95% confidence interval
for the difference in response rates between the
2 treatment groups would not be less than 15%.
Assuming that 60% of the randomized patients
would be clinically andmicrobiologically evaluable,
250 patients would need to be randomized per
treatment group to have a total of 300 evaluable
patients. No interim analyses were planned or
performed.
Secondary endpoints (proportion of patients
with a favorable clinical response in other popula-
tions and at other time points; proportion of
patients with an overall favorable microbiological
response) were analyzed using the same methods.
There was no adjustment for multiplicity since
only a single primary endpoint at one time point
had been prespecified.
Every patient who received at least 1 dose of
study drug was included in the safety analysis.
Adverse events occurring during the treatmentperiod or within 14 days after discontinuation of
study drug were tabulated. Differences in propor-
tions between the 2 treatment groups were com-
pared using the Fisher exact test for predetermined
safety endpoints.
Results
All 450 randomized participants were treated
with R1 dose of study drug (Fig. 1). Participating
centers randomized a median (interquartile range)
of 7 (3e11) patients. A total of 401 (89%) partic-
ipants completed the study. Of the 49 other
participants (20 randomized to receive ertapenem
and 29 randomized to receive ceftriaxone/metro-
nidazole) who prematurely left the study, 20
patients (9 in the ertapenem group and 11 in the
ceftriaxone/metronidazole group) were lost to
follow-up, moved, or withdrew consent. An addi-
tional 4 ertapenem and 5 ceftriaxone/metronida-
zole recipients experienced a clinical adverse
event resulting in discontinuation; 3 ertapenem
recipients and 5 ceftriaxone/metronidazole recip-
ients dropped out of the study due to the lack of
efficacy. The study was discontinued in another 9
patients for protocol violations, and 3 patients for
miscellaneous reasons. In total, 299 treated pa-
tients (66%) were clinically and microbiologically
evaluable at the primary TOC visit and constituted
the primary population for the evaluation of
efficacy, as specified a priori by the protocol.
Baseline patient demographic and disease char-
acteristics for treated patients and for clinicallyScreened = 492 
Randomized = 450
Etrapenem Treatment Group = 225 Ceftriaxone/Metronidazole Treatment Group = 225
MITT Population = 221 MITT Population = 217
Clinically Evaluable
Population = 206
Clinically Evaluable
Population = 202
Clinically and Microbiologically
Evaluable Population
= 148
Clinically and Microbiologically
Evaluable Population
 = 151
Figure 1 Patient accounting in this study. A total of 492 patients were screened for the study, of which 450 (91%)
were randomized. All randomized patients were treated with at least 1 dose of study drug. The primary population for
the analysis of efficacy was prespecified as the clinically and microbiologically evaluable subjects. All treated patients
were included in the safety analysis. MITT, modified intention to treat.
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ilar in both treatment groups (Table 1). At least 1
pathogen was recovered at baseline from intra-
operative and/or blood cultures in 70.7% and 72.4%
of treated patients in the ertapenem and ceftriax-
one/metronidazole groups, respectively. The most
commonly identified baseline pathogens were
Escherichia coli (51.6% in both treatment groups)
and Klebsiella pneumoniae (5.3% in the ertapenem
group and 4.9% in the ceftriaxone/metronidazole
group). The large majority of baseline isolates were
susceptible to both study regimens. Median dura-
tion of study therapywas 6 days for treated patients
in each treatment group, and 7 days for the
clinically and microbiologically evaluable popula-
tion in each treatment group. None, 6 (3%), and
25 (11%) participants treated with ertapenem and 8
(4%), 6 (3%), and 28 (12%) participants treated with
ceftriaxone/metronidazole received vancomycin
or teicoplanin, nonprotocol antimicrobial therapy
concurrently with study therapy after Day 1, andantimicrobial treatment during the 2 weeks after
study drug was discontinued, respectively.
Favorable response rates in each treatment
group are presented in Table 2 for the various
study populations and time points. In the primary
clinically and microbiologically evaluable popula-
tion, favorable clinical response rates were 143/
148 (96.6%) in the ertapenem treatment group and
146/151 (96.7%) in the ceftriaxone/metronidazole
treatment group at TOC; the difference (95% CI)
between the 2 treatment groups was 0.1 (4.8,
C4.6), satisfying the predetermined criteria for
noninferiority. Clinical response rates were also
similar in the clinically evaluable patients at TOC
for the 2 treatment groups. In the MITT analysis,
favorable clinical response rates were 93.2% for
ertapenem recipients and 93.1% for ceftriaxone/
metronidazole recipients. Overall microbiological
response rates in the clinically and microbiologi-
cally evaluable population at TOC were 97.9% in
the ertapenem treatment group and 96.7% in theTable 1 Baseline characteristics by treatment group
All treated
patientsa
Clinically and microbiologically
evaluable patients at
test-of-cure visitb
Ertapenem
(NZ 225)
Ceftriaxone/
metronidazole
(NZ 225)
Ertapenem
(NZ 148)
Ceftriaxone/
metronidazole
(NZ 151)
Male gender, n (%) 163 (72.4) 158 (70.2) 106 (71.6) 106 (70.2)
Age, mean years (range) 44.0 (18e88) 43.9 (18e88) 42.0 (18e85) 42.2 (18e87)
Baseline APACHE II score
median (range) 3.0 (0e17) 3.0 (0e20) 3.5 (0e14) 3.0 (0e20)
n (%)O 10 6 (2.7) 10 (4.4) 4 (2.7) 9 (6.0)
Site of infection, n (%)
Appendix 152 (67.6) 140 (62.2) 118 (79.7) 111 (73.5)
Colon 15 (6.7) 15 (6.7) 9 (6.1) 9 (6.0)
Gall bladder or biliary tract 11 (4.9) 17 (7.6) 5 (3.4) 7 (4.6)
Stomach or duodenum 24 (10.7) 32 (14.2) 7 (4.8) 11 (7.2)
Small intestine (beyond the
duodenum)
16 (7.1) 14 (6.2) 9 (6.1) 9 (6.0)
Other 7 (3.1) 7 (3.1) 0 (0.0) 4 (2.6)
Infectious process, n (%)
Abscess 35 (15.6) 40 (17.8) 22 (14.9) 27 (17.9)
Generalized peritonitis 85 (37.8) 67 (29.8) 65 (43.9) 49 (32.4)
Localized peritonitis 51 (22.7) 67 (29.8) 31 (20.9) 50 (33.1)
Gastrointestinal perforation 40 (17.8) 35 (15.6) 22 (14.9) 19 (12.6)
Other 14 (6.2) 16 (7.1) 8 (5.4) 6 (4.0)
Postoperative infection
at enrollment, n (%)
5 (2.2) 5 (2.2) 4 (2.7) 2 (1.3)
a All 450 randomized patients received R1 dose of study drug.
b Clinically and microbiologically evaluable patients comprised a subset of the clinically evaluable patients in whom a pathogen
was identified at baseline and a microbiological response could be assessed, and constituted the primary efficacy population.
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Treatment group Comparison
between
treatment groups
Ertapenem Ceftriaxone/metronidazole
na/Nb % na/Nb % Difference (95% CI)
Clinical response rates in clinically and microbiologically evaluable patients
End of therapy 147/148 99.3 152/155 98.1 1.3 (2.0, 5.0)
Test of curec 143/148 96.6 146/151 96.7 0.1 (4.8, 4.6)
Late follow-up 140/145 96.6 143/148 96.6 0.1 (4.9, 4.7)
Clinical response rates in clinically evaluable patients
End of therapy 205/206 99.5 203/207 98.1 1.4 (1.0, 4.4)
Test of cure 200/206 97.1 196/202 97.0 0.1 (3.6, 3.8)
Late follow-up 196/202 97.0 192/198 97.0 0.1 (3.7, 3.9)
Overall microbiological response rates in clinically and microbiologically evaluable patients
Test of cure 143/146 97.9 146/151 96.7 1.3 (3.0, 5.7)
Clinical response rates in MITTd patients
Test of cure 206/221 93.2 202/217 93.1 0.1 (4.8, 5.1)
a n: Number of evaluable patients with a favorable response.
b N: Number of evaluable patients.
c Primary endpoint and population for efficacy analysis.
d Modified intention-to-treat.ceftriaxone/metronidazole treatment group.
Table 3 shows response rates for individual patho-
gens. At TOC, 15 of 15 (100%) ertapenem recipients
and 7 of 9 (77.8%) ceftriaxone/metronidazole
recipients infected with P. aeruginosa and/or
Enterococcus faecalis had favorable clinical re-sponses. Time to defervescence was similar in both
treatment groups; approximately 50% of all pa-
tients with fever on the first day had become
afebrile by the third day of study therapy. No
patient in either treatment arm relapsed in the 4
weeks after discontinuation of study therapy.Table 3 Clinical response rates in clinically and microbiologically evaluable patients at the test-of-cure visit by
treatment group for the most common pathogens
Baseline pathogens Treatment group
Ertapenem
(NaZ 148)
Ceftriaxone/metronidazole
(NaZ 151)
n/mb (%) n/mb (%)
Enterobacter cloacae 5/5 100.0 3/3 100.0
Escherichia coli 105/109 96.3 104/109 95.4
Klebsiella oxytoca 2/2 100.0 3/3 100.0
Klebsiella pneumoniae 9/9 100.0 9/10 90.0
Proteus mirabilis 1/1 100.0 5/5 100.0
Pseudomonas aeruginosa 10/10 100.0 4/6 66.7
Bacteroides fragilis 7/8 87.5 3/3 100.0
Bacteroides sp. 4/4 100.0 1/1 100.0
Enterococcus faecalis 5/5 100.0 3/3 100.0
Enterococcus sp. 2/2 100.0 4/4 100.0
Staphylococcus epidermidis 4/4 100.0 2/2 100.0
Streptococcus milleri 3/4 75.0 1/2 50.0
Streptococcus sp. 7/7 100.0 7/7 100.0
Streptococcus viridans 2/2 100.0 6/6 100.0
Clostridium perfringens 3/3 100.0 2/2 100.0
a N, Number of evaluable patients.
b n, Number of evaluable patients with the specific pathogen identified at baseline and with a favorable clinical response at
TOC. m, Number of evaluable patients with the specific pathogen identified at baseline.
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adverse events were encountered with generally
comparable frequencies in both treatment groups
(Table 4). The most common drug-related adverse
events in each treatment group (ertapenem vs.
ceftriaxone/metronidazole recipients) were gas-
trointestinal (5.3% vs. 7.6%), most often nausea
(0.9% vs. 4.0%), diarrhea (2.7% vs. 1.8%), vomiting
(1.3% vs. 3.1%) and elevation of platelet count
(5.4% vs. 4.0%). No other specific drug-related
adverse events were reported in R4% of patients
in either treatment group. Ertapenem recipients
experienced less infusion-site reactions, whereas
ceftriaxone/metronidazole recipients had fewer
total serious adverse events. Four ertapenem
recipients (1.8%; 1 patient each with psychosis,
confusion, diarrhea, and abdominal infection) and
1 ceftriaxone/metronidazole recipient (0.4%; a pa-
tient with altered mental status and pulmonary
edema) developed serious drug-related adverse
events. Discontinuation rates due to drug-related
adverse events were similar in both groups. A
total of 6 deaths (4 patients in the ertapenem
group and 2 patients in the ceftriaxone/metroni-
dazole group) occurred during study therapy or
within 14 days thereafter. All deaths were judged
by the investigators to be unrelated to the studydrug and largely attributable to the complications
of severe infection and/or underlying comorbid
illness.
Information about healthcare resource utiliza-
tion was available in 218 (97%) of the participants
treated with ertapenem and 216 (96%) of the
participants treated with ceftriaxone/metronida-
zole. The median (range) number of doses was
6 (1e18) for recipients and 25 (2e70) for ceftriax-
one/metronidazole recipients. Twenty-five (11%)
ertapenem recipients and 19 (9%) of ceftriaxone/
metronidazole recipients spent time in a special-
ized care unit. Ten (5%) ertapenem recipients and
8 (4%) ceftriaxone/metronidazole recipients were
readmitted to the hospital after discharge. The
median (range) time in the hospital overall was
9 (3e51) days for participants given ertapenem
and 9 (3e67) days for participants given ceftriax-
one/metronidazole.
Discussion
Intra-abdominal infections encompass a wide va-
riety of infections and are operationally grouped
into uncomplicated or complicated cases.1e5,21e25
Complicated intra-abdominal infections requireTable 4 Frequency of adverse events (AE) by treatment group
Ertapenem Ceftriaxone/
metronidazole
Comparison between
treatment groups
NZ 225 NZ 225 Difference (95% CI)
Clinical adverse experiences
With any AE, n (%) 111 (49.3) 103 (45.8) 3.6 (5.7, 12.7)
With drug-relateda AE, n (%) 26 (11.6) 32 (14.2) 2.7 (9.0, 3.6)
With serious AEb, n (%) 34 (15.1) 19 (8.4) 6.7 (0.7, 12.8)d
With serious drug-relateda AE, n (%) 4 (1.8) 1 (0.4) 1.3 (0.9, 4.1)
With drug-relateda AE leading to
discontinuation of the studyb, n (%)
3 (1.3) 3 (1.3) 0.0 (2.7, 2.7)
Who diedc, n (%) 4 (1.8) 2 (0.9) 0.9 (1.6, 3.7)
Local Infusion/injection related events
Who had local reaction at siteb, n/m (%) 17/225 (7.6) 30/224 (13.4) 5.8 (11.7, 0.2)e
Laboratory adverse experiences
With any AE, n (%) 52 (23.1) 40 (17.8) 5.3 (2.1, 12.8)
With drug-relateda AE, n (%) 28 (12.4) 17 (7.6) 4.9 (0.7, 10.7)
With serious AE, n (%) 0 (0.0) 0 (0.0) e
With serious drug-relateda AE, n (%) 0 (0.0) 0 (0.0) e
With drug-relateda AE leading to
discontinuation of the study, n (%)
0 (0.0) 0 (0.0) e
a Determined by the investigator to be possibly, probably, or definitely related to study drug.
b Primary safety endpoints.
c All deaths resulted from complications of severe infections and/or underlying comorbid illnesses and were judged by the
investigators to be unrelated to study drug.
d P-valueZ 0.040.
e P-valueZ 0.046.
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antimicrobial therapy. Inadequate source control
and inappropriate antimicrobial therapy constitute
major causes of therapeutic failure. Selection of
antimicrobial drugs must take into account the
complex normal aerobic and anaerobic flora of
the bowel.3e5,23,25,26 Enterobacteriaceae and the
B. fragilis group of anaerobes are becoming in-
creasingly resistant to many drugs traditionally
used to treat mixed infections, even when they
are acquired in the community.12,27
Ertapenem, a long-acting parenteral Group I
carbapenems,13 is active in vitro against most
aerobic and anaerobic bacteria found in commun-
ity-acquired intra-abdominal infections.7e11,15,28,29
Ertapenem is not reliably active against entero-
cocci, methicillin-resistant Staphylococcus aureus,
P. aeruginosa and other nonfermentative aerobic
gram-negative bacilli. Ertapenem was as effica-
cious as piperacillinetazobactam16 or ceftriaxone
plus metronidazole18 in previous double-blind ran-
domized clinical trials of the therapy of compli-
cated intra-abdominal infections.
The findings of the present randomized open-
label study are consistent with previously pub-
lished results. In this study, the large majority of
patients in both treatment arms had appendicitis
and APACHE II scores% 5. The most commonly
isolated pathogens at baseline in our study were
E. coli and K. pneumoniae. Favorable clinical
response rates exceeded 96% for both study
regimens at the TOC visit. Although neither
regimen had consistent activity against P. aeru-
ginosa and enterococci, most patients infected
with these pathogens responded favorably, sug-
gesting that routine enterococcal or pseudomo-
nal coverage may not always be critical in
treating polymicrobial intra-abdominal infections
in patients undergoing surgery.3,5 Serious drug-
related adverse experiences were uncommon in
both treatment groups. The most common drug-
related adverse events were diarrhea and other
gastrointestinal disorders, and elevated platelets
counts. Discontinuations due to drug-related
adverse experiences were infrequent.
Ertapenem retains activity against most Enter-
obacteriaceae producing extended spectrum
b-lactamases.10,30,31 As these resistant bacteria
continue to spread in both the hospital and
community settings, ertapenem may become an
increasingly attractive option for the empirical
therapy of intra-abdominal infections.7,8,29,30 The
results of this randomized open-label study sup-
port ertapenem monotherapy as an effective
treatment option for patients with complicated
intra-abdominal infections.Acknowledgments
We thank all the patients who participated in the
study. We also appreciate the many contributions
of the entire OASIS II Study Team:
Dr. Anthony Allworth, Queensland, Australia
Prof. Paolo Pederzoli, Verona, Italy
Prof. Dr. Mario Mantovani, Saˆo Paulo, Brazil
Prof. Enrico Bertolotto, Genova, Italy
Prof. Dr. Sergio Brenner, Curitiba, Brazil
Prof. Renato Moretti, Firenze, Italy
Dr. Maria Isabel Campos, Chile
Prof. Marco Sacchi, Latina, Italy
Prof. Wang Fu/Zhang Yingyuan, Shanghai, China
Prof. Piero Chirletti, Roma, Italy
Prof. Zhu Zhenggang, Shanghai, China
Prof. Eugenio Santoro, Roma, Italy
Prof. Wei Junmin/ Dr. Liu Yalin Beijing, China
Prof. Francesco Tonelli, Firnze, Italy
Prof. Tang Weisong, Beijing, China
Prof. Renzo Dionigi, Varese, Italy
Dr. Erix Bozo´n, Bogota´, Colombia
Prof. Gaetano Salamone, Palermo, Italy
Dr. Oscar Garcı´a, Bogota´, Colombia
Dr. Colin Ng Leong Liong, Kuala Lumpur, Malaysia
Dr. Mate Skegro, Zagreb, Croatia
Prof. Jasmi Ali Yaakob, Kuala Lumpur, Malaysia
Dr. Petar Kirac, Zagreb, Croatia
Dr. Nora Quintero, Guadalajara, Mexico
Dr. Emilio Dominguez, Mannheim, Germany
Dr. Ramo´n Alvarado, Lima, Peru
Prof. Dr. Andreas Hirner, Bonn, Germany
Dr. Luis Martins, Lima, Peru
Prof. Dr. Markus Bu¨chler, Heidelberg, Germany
Prof. Narciso S. Navarro, Manila, Philippines
Prof. Dr. Harald Schramm, Gera, Germany
Prof. Boris R.Gelfand, Moscow, Russia
Dr. Thomas Manger, Gera, Germany
Prof. Mikhail M.Abakumov, Moscow, Russia
Prof. Dr. Jacob Izbicki, Hamburg, Germany
Prof. Sergey G. Shapovalyants, Moscow, Russia
Prof. Dr. Horst-Guenther Rau, Dachau, Germany
Dr. Pretorius, Pretoria, South Africa
Dr. Johannes Schmidt, Essen, Germany
Dr. Salvador Lledo-Matoses, Valencia, Spain
Dr. Walter Asperger, Halle, Germany
Dr. Jose A. Soro-Gosalvez, Baleares, Spain
Prof. Dr. Peter Kujath, Lu¨beck, Germany
Dr. Ignacio Iturburu Belmonte, Bilbao (Vizcaya),
Spain
Dr. Jens Koehler, Nu¨rnberg, Germany
Dr. Antonio Colas Vicente, Madrid, Spain
Prof. Francesco Salvestrini, Siena, Italy
Dr. Maw-Chang Sheen, Kaohsiung, Taiwan
Ertapenem versus ceftriaxone and metronidazole 33Prof. Lorenzo Capussotti, Torino, Italy
Dr. Ming-Tsan Lin, Taipei, Taiwan
Prof. Stefano M. Giulini, Brescia, Italy
Dr. Dah-Shyong Yu, Taipei, Taiwan
Prof. Domenico Marrano, Bologna , Italy
Dr. Darin Lohsiriwat, Bangkok, Thailand
Prof. Davide D’Amico, Padova, Italy
Prof. Frank Branicki, Al Ain, Abu Dhabi, United
Arab Emirates
Prof. Andrea Sortini, Italy
Trees Vanryckeghem, MSD, Brussels, Belgium
Prof. Giuseppe Donini, Ferrara, Italy
Karlien Van Belleghem, MSD, Brussels, Belgium.
References
1. Rotstein OD, Meakins JL. Diagnostic and therapeutic
challenges of intraabdominal infections. World J Surg
1990;14:159e66.
2. Barie PS. Management of complicated intra-abdominal
infections. J Chemother 1999;11:464e77.
3. Mazuski JE, Sawyer RG, Nathens AB, Dipiro JT, Schein M,
Kudsk KA, et al. The surgical infection society guidelines
on antimicrobial therapy for intra-abdominal infections:
an executive summary. Surg Infect (Larchmt) 2002;3:
161e73.
4. Holzheimer RG, Muhrer KH, L’Allemand N, Schmidt T,
Henneking K. Intraabdominal infections: classification,
mortality, scoring and pathophysiology. Infection 1991;19:
447e52.
5. Solomkin JS, Mazuski JE, Baron EJ, Sawyer RG, Nathens AB,
Dipiro JT, et al. Guidelines for the selection of anti-
infective agents for complicated intra-abdominal infec-
tions. Clin Infect Dis 2003;37:997e1005.
6. Wacha H, Hau T, Dittmer R, Ohmann C. Risk factors
associated with intraabdominal infections: a prospective
multicenter study. Peritonitis Study Group. Langenbecks
Arch Surg 1999;384:24e32.
7. Goldstein EJ, Snydman DR. Intra-abdominal infections:
review of the bacteriology, antimicrobial susceptibility
and the role of ertapenem in their therapy. J Antimicrob
Chemother 2004;53(Suppl. 2):ii29e36.
8. Curran M, Simpson D, Perry C. Ertapenem: a review of its
use in the management of bacterial infections. Drugs 2003;
63:1855e78.
9. Goldstein EJ, Citron DM, Vreni MC, Warren Y, Tyrrell KL.
Comparative in vitro activities of ertapenem (MK-0826)
against 1,001 anaerobes isolated from human intra-abdom-
inal infections. Antimicrob Agents Chemother 2000;44:
2389e94.
10. Livermore DM, Oakton KJ, Carter MW, Warner M. Activity of
ertapenem (MK-0826) versus Enterobacteriaceae with po-
tent beta-lactamases. Antimicrob Agents Chemother 2001;
45:2831e7.
11. Livermore DM, Sefton AM, Scott GM. Properties and
potential of ertapenem. J Antimicrob Chemother 2003;
52:331e44.
12. Pelak BA, Woods GL, Teppler H, Friedland I, Bartizal K,
Motyl M. Comparative in-vitro activities of ertapenem
against aerobic bacterial pathogens isolated from patients
with complicated intra-abdominal infections. J Chemother
2002;14:227e33.13. Shah PM, Isaacs RD. Ertapenem, the first of a new group of
carbapenems. J Antimicrob Chemother 2003;52:538e42.
14. Solomkin J, Teppler H, Graham DR, et al. Treatment of
polymicrobial infections: post hoc analysis of three trials
comparing ertapenem and piperacillinetazobactam.
J Antimicrob Chemother 2004;53(Suppl. 2):ii51e7.
15. Wexler HM. In vitro activity of ertapenem: review of
recent studies. J Antimicrob Chemother 2004;53(Suppl. 2):
ii11e21.
16. Solomkin JS, Yellin AE, Rotstein OD, Christou NV,
Dellinger EP, Tellado JM, et al. Ertapenem versus
piperacillin/tazobactam in the treatment of complicated
intraabdominal infections: results of a double-blind, ran-
domized comparative phase III trial. Ann Surg 2003;237:
235e45.
17. Teppler H, McCarroll K, Gesser RM, Woods GL. Surgical
infections with enterococcus: outcome in patients treated
with ertapenem versus piperacillinetazobactam. Surg In-
fect (Larchmt) 2002;3:337e49.
18. Yellin AE, Hassett JM, Fernandez A, Geib J, Adeyi B,
Woods GL, et al. Ertapenem monotherapy versus combina-
tion therapy with ceftriaxone plus metronidazole for
treatment of complicated intra-abdominal infections in
adults. Int J Antimicrob Agents 2002;20:165e73.
19. National Committee for Clinical Laboratory Standards
NCCLS document M27-A. Performance standards for anti-
microbial disk susceptibility tests. 7th ed. 2000.
20. National Committee for Clinical Laboratory Standards.
NCCLS document M7-A5 Wayne P. Methods for dilution
antimicrobial susceptibility tests for bacteria that grow
aerobically. 5th ed. 2000.
21. dela Pena AS, Asperger W, Warren B, Kafka R, Raz R,
Shivaprakash M, et al. Microbiological results from a ran-
domized, open-label study of etapenem vs. piperacillin/
tazobactam for the treatment of community-acquired
intraabdominal infections (IAI) requiring surgery. Pre-
sented at the 14th European Congress of Clinical Microbi-
ology and Infectious Diseases. Prague, Czech Republic. May
1e4, 2004; Poster P1685.
22. dela Pena AS, Asperger W, Kockerling F, Raz R, Kafka R,
Warren B, et al. Ertapenem versus piperacillin/tazobactam
for the treatment of intra-abdominal infections (IAI)
requiring surgical intervention (OASIS-1): results of a pro-
spective, randomized, open-label study. Presented at the
14th European Congress of Clinical Microbiology and In-
fectious Diseases. Prague, Czech Republic. May 1e4, 2004.
Poster #P1686.
23. Christou NV, Turgeon P, Wassef R, Rotstein O, Bohnen J,
Potvin M. Management of intra-abdominal infections.
The case for intraoperative cultures and comprehensive
broad-spectrum antibiotic coverage. The Canadian Intra-
abdominal Infection Study Group. Arch Surg 1996;131:
1193e201.
24. Cooper GS, Shlaes DM, Salata RA. Intraabdominal in-
fection: differences in presentation and outcome between
younger patients and the elderly. Clin Infect Dis 1994;19:
146e8.
25. Elsakr R, Johnson DA, Younes Z, Oldfield III EC. Antimicro-
bial treatment of intra-abdominal infections. Dig Dis 1998;
16:47e60.
26. Goldstein EJ. Intra-abdominal anaerobic infections: bacte-
riology and therapeutic potential of newer antimicrobial
carbapenem, fluoroquinolone, and desfluoroquinolone ther-
apeutic agents. Clin Infect Dis 2002;35:S106e11.
27. Hecht DW. Prevalence of antibiotic resistance in anaerobic
bacteria: worrisome developments. Clin Infect Dis 2004;
39:92e7.
34 N.S. Navarro et al.28. Aldridge KE. Ertapenem (MK-0826), a new carbapenem:
comparative in vitro activity against clinically significant
anaerobes. Diagn Microbiol Infect Dis 2002;44:181e6.
29. Brismar B, Nord CE. Monobactams and carbapenems for treat-
mentof intraabdominal infections. Infection1999;27:136e47.
30. Gesser RM, McCarroll K, Teppler H, Woods GL. Efficacy of
ertapenem in the treatment of serious infections caused byEnterobacteriaceae: analysis of pooled clinical trial data.
J Antimicrob Chemother 2003;51:1253e60.
31. Nijssen S, Florijn A, Bonten MJM, Schmitz FJ, Verhoef J,
Fluit AC. Beta-lactam susceptibilities and prevalence of
ESBL-producing isolates among more than 5000 European
Enterobacteriaceae isolates. International J Antimicrob
Agents 2004;24:585e91.
